Clinical trials: Breast Cancer, Estrogen Receptor-Positive
Breast Cancer Female, Estrogen Receptor Positive Tumor
The MASTER Study (MAmmary Cancer STatin ER Positive Study)
Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed.
- Trial name
- NCT04601116
- Testing
- Atorvastatin 80 Mg Oral Tablet
- Where
- Denmark
- Volunteers
- 3,360 people
- Sponsor
- Aarhus University Hospital
ER+ HER2- Advanced Breast Cancer
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to…
- Trial name
- NCT04541433
- Testing
- AZD9833
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
- Trial name
- NCT00068328
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 85 sites in United States
- Volunteers
- 1,706 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Estrogen Receptor Negative, Estrogen Receptor Positive
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative
- Trial name
- NCT01281163
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ
Broccoli Sprout Extract in Treating Patients With Breast Cancer
This randomized pilot trial studies broccoli sprout extract in treating patients with breast cancer. Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers.
- Conditions
- Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive
- Trial name
- NCT01753908
- Testing
- Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Biology Guided Therapy for Breast Cancer for ER Positive
There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- SPOCK (NCT04965688)
- Testing
- Biopsy-Guided Therapy Selection
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Breast Cancer
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells.
- Trial name
- NCT00049062
- Testing
- anastrozole, gefitinib
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
HER2-positive Breast Cancer, Breast Cancer Metastatic
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
This study will determine the recommend dose of palbociclib in combination with letrozole and another medication, Ado-trastuzumab emtansine (T-DM1).
- Trial name
- NCT03709082
- Testing
- Palbociclib 75mg, Letrozole 2.5mg, T-DM1
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
The purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0…
- Trial name
- FELINE (NCT02712723)
- Testing
- Letrozole, Ribociclib
- Where
- 13 sites in United States
- Volunteers
- 121 people
- Sponsor
- Qamar Khan
Metastatic Breast Cancer
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
- Trial name
- NCT06110793
- Testing
- Lenvatinib, Pembrolizuma, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer.
- Trial name
- NCT01594216
- Testing
- Ruxolitinib, Exemestane
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
This phase Ib trial studies the best dose of berzosertib when given together with the usual treatment (radiation therapy) in treating patients with triple negative or estrogen receptor and/or progesterone receptor positive, HER-2…
- Conditions
- Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04052555
- Testing
- Berzosertib, Biospecimen Collection, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, HER2-positive Breast Cancer
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
To evaluate the efficacy and safety of the SHR6390 in combination with anastrozole, pyrotinib, and trastuzumab in patients with ER-positive, HER2-positive breast cancer in the neoadjuvant setting.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer
- Trial name
- NCT04236310
- Testing
- SHR6390, Anastrozole, Pyrotinib
- Volunteers
- 37 people
- Sponsor
- Ruijin Hospital
Breast Cancer, Metastatic Breast Cancer
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer
- Trial name
- EVOLVE-BDT (NCT07340541)
- Testing
- SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine
- Where
- 6 sites in United States
- Volunteers
- 700 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Estrogen Receptor Negative, Estrogen Receptor Positive
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01319539
- Testing
- Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Estrogen Receptor Positive Breast Cancer
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor Positive Breast Cancer, Node-negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- NCT02823262
- Testing
- Breast Cancer Treatment Decision Aid for women 70+, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Beth Israel Deaconess Medical Center
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom.
- Trial name
- NCT06450873
- Testing
- Coriolus Versicolor Extract, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
The purpose of this study is to look at the amount of cancer cells in the blood of participants who are being treated with denosumab.
- Conditions
- Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT03070002
- Testing
- Denosumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Breast Cancer
Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity
One out of 8 women will develop breast cancer (BC) in her lifetime and despite improvements in therapeutic strategies it remains one of the main causes of cancer-related mortality for women in industrialized countries.
- Trial name
- AteBrO (NCT04630210)
- Testing
- Letrozole, Atezolizumab
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This is an open-label, dose-finding, safety, pharmacokinetics (PK), and evidence-of-activity study of GDC-0927 in postmenopausal women with locally advanced or metastatic Estrogen Receptor Positive (ER+) Human Epidermal Growth…
- Trial name
- NCT02316509
- Testing
- GDC-0927
- Where
- 13 sites in United States, Spain
- Volunteers
- 43 people
- Sponsor
- Genentech, Inc.